ANGLE plc (GB:AGL) has released an update.
ANGLE plc, a leading liquid biopsy company, intends to raise approximately £8.5 million through a combination of new share placements and subscriptions, alongside an open offer, to further commercialize its Parsortix system and support growth. The company aims to use these funds for expanding its sales force, developing assays, and building clinical laboratory capabilities, with a goal of reaching cashflow breakeven by the end of 2025. This fundraising follows significant deals with pharmaceutical giants such as Eisai and AstraZeneca, signaling strong market confidence and potential for robust growth.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
